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Abstract
Background: Although providers have been using supplemental oxygen therapy in the treatment of
myocardial infarction for over 100 years, there are currently no current guidelines established for the
treatment of normoxic patients. Research has shown possible worsened outcomes for uncomplicated
myocardial infarctions when oxygen is used; including worsened ischemic area and increased arrhythmias.
The aim of this systematic review is to evaluate the research on whether or not supplemental oxygen therapy
can cause increased cardiac events for patients presenting with an uncomplicated AMI.
Methods: An exhaustive search of the literature was performed using MEDLINE-Ovid, Web of Science, and
ClinicalKey. Key words included myocardial infarction, oxygen, and oximetry.
Results: Out of the 16 relevant articles found, only two articles fit all inclusion and exclusion criteria. Both
studies showed evidence of increase infarct size and cardiac arrhythmias with supplemental oxygen use in
uncomplicated myocardial infarctions. The overall quality of evidence was found to be moderate. Further
studies are needed to show the long-term morbidity and mortality.
Conclusion: The use of supplemental oxygen in an uncomplicated AMI has been shown to cause an increase
in infarct size as well as increased cardiac arrhythmias and recurrent myocardial infarcts. Although there is
evidence to support short term worsened cardiac events, there are currently no studies for long-term
morbidity and mortality. Further research is required to determine the long-term effects of oxygen
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Background: Although providers have been using supplemental oxygen therapy in the treatment 
of myocardial infarction for over 100 years, there are currently no current guidelines established 
for the treatment of normoxic patients. Research has shown possible worsened outcomes for 
uncomplicated myocardial infarctions when oxygen is used; including worsened ischemic area 
and increased arrhythmias. The aim of this systematic review is to evaluate the research on 
whether or not supplemental oxygen therapy can cause increased cardiac events for patients 
presenting with an uncomplicated AMI. 
Methods:  An exhaustive search of the literature was performed using MEDLINE-Ovid, Web of 
Science, and ClinicalKey. Key words included myocardial infarction, oxygen, and oximetry. 
Results:  Out of the 16 relevant articles found, only two articles fit all inclusion and exclusion 
criteria. Both studies showed evidence of increase infarct size and cardiac arrhythmias with 
supplemental oxygen use in uncomplicated myocardial infarctions. The overall quality of 
evidence was found to be moderate. Further studies are needed to show the long-term morbidity 
and mortality. 
Conclusion:  The use of supplemental oxygen in an uncomplicated AMI has been shown to 
cause an increase in infarct size as well as increased cardiac arrhythmias and recurrent 
myocardial infarcts. Although there is evidence to support short term worsened cardiac events, 
there are currently no studies for long-term morbidity and mortality. Further research is required 
to determine the long-term effects of oxygen supplementation for normoxic patients with acute 
myocardial infarctions. 
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Increased Cardiac Events with Use of Supplemental Oxygen 




 Supplemental oxygen therapy is administered for more than 90% of patients presenting 
with an acute myocardial infarction (AMI)1  and has been for over 100 years.2  However, due to 
research on therapeutic oxygen showing ambiguous results, the 2013 ACCF/AHA guidelines do 
not currently have any recommendation for its use in therapy for normoxic patients.3   
Human studies on this topic stem all the way back to 1976, where it was found that 
oxygen therapy might be beneficial in myocardial ischemia, 4  especially when used for patients 
with oxygen saturations <90%. 5  In hypoxic conditions, the increased oxygen is thought to be 
due to supplying the surrounding hypoxic tissue with needed oxygen. 6  However, in normoxic 
myocardium, data has shown that supplemental oxygen leads to a decrease in cardiac output and 
coronary outflow. 6-8   
This physiologic effect with normoxic myocardium is due to hyperoxia, the over 
saturation of hemoglobin molecules at a PO2 of approximately 90 mmHg.
8 Supplemental oxygen 
therapy delivered through a facemask increases blood PO2 to approximately 250 mmHg; 
resulting in oversaturation of the hemoglobin and excess free oxygen in the blood stream.8 The 
free oxygen then forms reactive oxygen species (ROS) that reacts with nitric oxide, leading to 
the inactivation of its vasodilatory effects and continued constriction of the coronary blood flow. 
The theory of this physiologic effect has been further supported through lab results that showed 
increased lactate levels in the coronary venous system following 100% oxygen supplementation 
in myocardial infarctions. 7  
 8 
With the mixed results found over the last 100 years, it is unknown whether the tradition 
of using oxygen therapy is beneficial or harmful to patients, and the harm of oxygen therapy has 
not been further evaluated until recently. The aim of this systematic review is to evaluate the 
research on whether or not supplemental oxygen therapy can cause increased cardiac events for 
patients presenting with an uncomplicated AMI. 
METHODS 
An exhaustive search of the literature was performed using MEDLINE-Ovid, Web of 
Science, and ClinicalKey. Keywords used included: myocardial infarction, oxygen, and 
oximetry. Studies were required to be done on human participants, be written in English, include 
patients with an uncomplicated STEMI diagnosis, take ischemic area measurements by labs or 
imaging, record reoccurrence rates of AMI, and monitor for cardiac arrhythmias. Bibliographies 
of studies and other relevant articles were searched for further sources. Articles were assessed for 
quality using the Grading of Recommendations, Assessment, Development, and Evaluation 
(GRADE). 9  
RESULTS 
A total of 16 articles were reviewed for relevancy. Four articles fit inclusion criteria that 
were all randomized controlled trials. 10-13  One of the studies 11  found may have contained topic 
material, but was excluded due to not being in the English language. Another article was found 
that contained all of the inclusion criteria, but was excluded due to being a pilot study without 
final results. 13  No additional articles were found by searching the references of the included 
studies. See Table I for a break down of the GRADE criteria used for each included article. 
Rawles and Kenmure (1976) 
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 This double-blinded, randomized control trial 10  looked at two hundred consecutive 
patients presenting to the cardiac unit with an uncomplicated myocardial infarction within the 
last 24 hours. The patients were split into two groups upon presentation, one that received 
supplemental oxygen at 6L/min via mask (N=105) and the other that was placed on 6L/min 
compressed air via mask (N=95) for 24 hours. The air units were covered to allow for blinding. 
The participants were only allowed known oxygen therapy if they developed left ventricular 
failure or cardiac arrest during their stay in the unit, at which point they were unhooked from the 
blinded unit and attached to a wall mounted oxygen therapy. The participants were then left in 
their initial therapy groups for intent to treat protocol. 10  
 The study excluded any patients that had heart failure, chronic obstructive pulmonary 
disorder (COPD) or breathlessness due to any other cause. The patients were then diagnosed 
with AMI if they had >30 minutes of chest pain unaffected by position, respirations, rest, 
glyceryl trinitrate, rise in serum aspartate aminotransferase levels above 20 IU/ML, and 
abnormal ECGs with sequential ST and T wave changes with or without Q waves. Any patients 
included in the study originally that were found to have a different diagnosis than AMI were then 
excluded (18 in the compressed air group and 25 in the oxygen group). 10  
 Every participant had ECGs recorded for two minutes every hour for the first 24 hours. 
Heart rate, arrhythmias, and ectopic beats were noted from the recordings. Any other arrhythmias 
were also recorded. Serial aspartate aminotransferase levels were taken from every patient. The 
results were then analyzed using χ2 test with Yate’s correction for comparison of frequencies and 
Student t test for comparison of mean values. 10  
 10 
 Mean age, sex distribution, mean aspartate aminotransferase, arrhythmias, and deaths 
were recorded by Rawles and Kenmure and are available in Table II below. Results showed the 
mean serum aspartate aminotransferase level to be significantly higher (P<0.05) in the oxygen 
group (99.9; 95% CI 85.7-114.1) than it was in the compressed air group (80.7; 95% CI 67.5-
93.9). It was also noted that there was a statistically significant (P<0.05) increase in the 
occurrence of sinus tachycardia in the oxygen group than in the compressed air group (23 
patients vs. 11 patients). Death was also recorded, and it was found that patients in the 
supplemental oxygen group had increased mortality compared to the compressed air group (9 
deaths vs. 3 deaths). 10  
Stub et al (2015) 
 This multicenter, blinded, and computer randomized control study 12  included 441 
confirmed STEMI patients. It was done to look at whether normoxic (O2 saturation ≥94%) 
patients presenting with a STEMI diagnosis are harmed by use of supplemental oxygen therapy. 
The primary end point was AMI size and was monitored by use of troponin I and creatine kinase 
levels in STEMI patients with or without oxygen. Secondary end points included recurrent 
AMIs, cardiac arrhythmias (sustained and non-sustained ventricular and atrial tachycardia), AMI 
size via cardiac magnetic resonance imaging (CMR), and mortality. 12  
To determine inclusion into the study, paramedics in the field were used to determine if a 
patient was suffering from a STEMI according to 12-lead ECG (ST elevation of ≥0.1mV in 2 
contiguous limb leads, ≥0.2mV in contiguous chest leads, or new LBBB pattern). They then 
opened a randomized opaque envelope to determine if the patient was to be given 8L/min 
oxygen via mask (N=218) or to be left on room air (N=223). The room air group was only 
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allowed oxygen therapy during the trial if their O2 saturation fell below 94% at which point 
oxygen was titrated to maintain a saturation of 94%. Only 7.7% of the room air group needed 
oxygen therapy at any given time. Further inclusion criteria outside of ECG results included 
being ≥18 years of age and having chest pain for <12 hours. Exclusion criteria were if the patient 
had an O2 saturation less than 94% at presentation, had a recent nebulizer therapy that used O2, 
had O2 therapy given before randomization, had altered mental status, had planned transport to a 
nonparticipating hospital, or was ruled to not have a STEMI by the physician upon arrival to the 
hospital. A flow chart of exclusion criteria can be seen with Figure I. 12  
The general characteristics for every participant were monitored (Table III). Serial 
troponin I and creatine kinase assays were taken at baseline, every six hours for the first 24 
hours, and then every 12 hours until 72 hours post admission. Median peak levels were then used 
to determine comparisons for the two groups. Area under the curve (AUC) for serum levels was 
also conducted using trapezoidal integration with multiple imputations using the Markov Chain 
Monte Carlo method for patients missing ≥1 biomarker assay. Geometric means, ratios and 95% 
CI were done for each primary end point using Student t tests on log-transformed data with 
comparison of groups obtained after back-transformation. Secondary end points were then 
measured at discharge and again at 6 months. Geometric means of the infarct size at 6 months 
was compared across groups using the Student t test on the log-transformed data with 
comparison of groups obtained after back-transformation. Group differences were then compared 
using the Wilcoxon rank-sum test. The relationship between the troponin I and creatine kinase 
results were then compared to the CMR results using the Spearman rank correlations. 12  
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The primary end point results (Table IV) found that the differences between the mean 
peaks for troponin I were not statistically significant (P=0.18) between the two groups (57.4 vs 
48.0 µg/L; ratio 1.20; 95% CI 0.92-1.56). However, the creatine kinase was found to be 
significantly elevated (P=0.01) for the patients given oxygen (1948 vs 1543 U/L; ratio 1.27; 95% 
CI 1.04-1.52). 12  
Secondary end points studied found that in-hospital recurrent myocardial infarctions 
(5.5% vs 0.9%; P=0.006) and cardiac arrhythmias (40.4% vs 31.4%; P=0.05) were increased in 
the oxygen group. However, during the 6-month follow up, the two groups did not appear to 
have any differences. Myocardial infarct size studied through use of CMR found baseline 
characteristics to be similar at discharge. There were 139 patients (65 oxygen and 74 room air) 
who were then able to return to clinic to have a 6-month follow up CMR performed. These 
results showed a significant (P=0.04) increase in infarct size for the patients given oxygen 
supplementation (20.3g vs 13.1g). During their stay in the hospital, mortality results showed that 
the oxygen group had 4 deaths (1.8%) and the room air group had 10 (4.5%). 12  
The authors state the limitations of the study to be the inability to blind all participants, 
exclusion of participants due to physician rule out of STEMI, and small follow up for CMR 
results. The cardiology team, patients and paramedics were all unable to be blinded to treatment. 
However, the follow up coordinator, data analyst, and the statistician were all blinded to 
treatment groups. This should be substantial enough blinding to limit any biases in results. The 
exclusions due to physician rule out of STEMI were similar numbers in both groups (oxygen 
N=79; room air N=68) and had similar enough baseline characteristics to have substantial 
selection bias not occur. Limited CMR follow up was due to patients being unable to make the 
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return visit to the base hospital. Although the follow up numbers were similar for each group, the 
total population was relatively small. As a secondary end point, this does not limit the study, as 
further evaluation of mortality and morbidity is required. 12  
DISCUSSION 
Part of a treatment plan for a STEMI is that each patient is given morphine for pain, 
oxygen, nitroglycerine for vasodilation, and aspirin for anticoagulation effects (MONA). 14  
Although no current guidelines have recommendations for oxygen use in all AMI patients, the 
use of supplemental oxygen therapy by physicians for all patients presenting with AMIs is high. 1   
Currently there have been no influential studies to show improved or worsened long-term 
outcomes with oxygen use. Even with the lack of evidence, providers are still continuing to use 
supplemental therapy for more than 90% of patients. 1  Some providers have taken to 
symptomatic relief studies for reasoning behind supplementing its use. For example, both 
analgesic effects and anxiolytic effects of oxygen have been thought to occur in patients 
presenting with an AMI. 15  However, a recent study in 2013 has shown that there does not seem 
to be any analgesic effects when oxygen is compared to room air use in STEMIs. 16  If providers 
are going to use supplemental oxygen therapy without any strong evidence supporting the use of 
oxygen being beneficial, it must be determined if there is harm that can occur from its use.  
The only evidence directed at the harm of oxygen therapy were those discussed in this 
review. Both articles 10,12  showed indications of worsened cardiac events due to supplemental 
oxygen therapy use. Increased serum cardiac enzymes with oxygen use was observed in both 
studies, a finding that implies an increased ischemic area of the heart. This finding was also 
backed up by CMR that showed an average of approximately 7g increase in infarct size after 6 
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months when compared to AMI patients on room air. 12  Not only did patients on oxygen have 
increased infarct sizes, but research also noted increased arrhythmias and recurrent myocardial 
infarctions while in the hospital. 12  Therefore, it can be concluded that there is an increase in 
cardiac events with the use of supplemental oxygen in an uncomplicated AMI. Unfortunately, at 
this time it is not evident whether or not supplementary oxygen has increased risk for long-term 
morbidity and/or mortality. Although these findings might lead to further morbidities for 
patients, it cannot be certain from the available information if they will result in any long-term 
effects. Further studies on the morbidity and mortality effects of supplemental oxygen are still 
required before official guidelines should be implemented for or against the use of oxygen in 
AMI. 
These studies 10,12  were evaluated using the GRADE criteria, and the results can be seen 
in Table I. The Rawles and Kenmure study had the biggest limitation due to age. As it is from 
1976, there were less evidence-based criteria required for studies at that time, less technology, 
and fewer lab tests available. For example, it is not indicated how many patients required 
supplemental oxygen therapy after having cardiac arrest or left ventricular heart failure. 
Although the patients were treated with intent to treat for results, the difference in which patients 
were requiring the oxygen could result in a bias in the results. Also, the lack of pulse oximetry 
technology limits the study as to whether the patients were hypoxic or normoxic at presentation, 
a criterion that currently has ACCF/AHA guidelines for supplemental oxygen use. Another 
notable flaw in the Rawles and Kenmure study is the use of aspartate aminotransferase to 
monitor heart ischemia. Although aspartate aminotransferase is found in the highest 
concentration in heart tissues, it is also found in erythrocytes, liver, muscle, pancreas, and 
kidneys. 17  With a diagnosis of AMI, it is likely the increased levels were from the heart tissue; 
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however, with the given information, it is impossible to tell for sure where the increased 
aspartate aminotransferase came from. With these limitations, the Rawles and Kenmure study 
cannot stand-alone for whether or not oxygen therapy is harmful for AMI patients.  
The Stub et al study 12  was found to have a few limitations in their work as well. One 
limitation was the use of 8L/min oxygen, as decided per Australian protocol. Although it is not a 
direct limitation of the information, it is still unknown if low oxygen supplementation or other 
methods of oxygen deliver carry the same risks found. A non-substantial selection bias was also 
discussed as a limitation in this article. Because STEMIs had to be determined in the field by a 
paramedic, there was a resultant loss of participants from the provider ruling out an AMI. 
Because of the limited quantity of participants allowed to participate, this could have lead to a 
resultant selection bias. However, selection bias is not substantial because each group lost 
approximately the same amount of participants. Another limitation is the high loss of follow up 
for the CMR at 6 months. Although populations were almost even for each group when it came 
to follow up, the decrease in sample size is not significant enough to determine whether oxygen 
use can have increased risk associated with long term results. 
Some limitations to this systematic review paper include the inclusion of only two 
articles on the topic resulting in a decreased precision in the results. However, the strong 
evidence found in the Stub et al study, 12  and the consistency seen between the two articles 
increases the precision. The only inconsistency observed while undergoing the research was seen 
in mortality. The Rawles and Kenmure study 10  found that patients on oxygen therapy had a 
three-fold increase in mortality (9 deaths vs. 3 deaths), whereas the Stub et al study 12  found 
more than double the amount of deaths for patients on room air than patients given oxygen (10 
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deaths vs. 4 deaths). This inconsistency may be insignificant given the relatively small numbers 
in each subgroup and the results being secondary outcomes in both studies. Due to these 
limitations, the overall quality of evidence included in this research is a moderate rating 
according to the GRADE scale. 
The increased risk for morbidity and the inconsistency with mortality must be followed 
up on with larger studies that focus on them as primary outcomes. One study that is currently 
being worked on in Sweden is the DETermination of the role of OXygen in suspected Acute 
Myocardial Infarction trial (DETO2X-AMI Trial) by Hofmann et al. 13  This study will include 
6600 normoxic AMI patients that are split into either 6L/min oxygen or room air. The studies 
primary outcome will be 1-year all-cause mortality with secondary end points of 30-day 
mortality, cardiac events, and health economy. With the results of this new study 13  it is hopeful 
that the question of whether or not supplemental oxygen therapy puts an AMI patient at 
increased risk of harm will be answered more clearly.  
CONCLUSION 
The use of supplemental oxygen in an uncomplicated AMI has been shown to cause an 
increase in infarct size as well as increased cardiac arrhythmias and recurrent myocardial infarcts 
while admitted in the hospital. Given this information, it is uncertain why there are no current 
guidelines for the use of supplemental therapy in uncomplicated AMIs. The number one rule for 
health providers is to do no harm to patients. However, even with this expectation of doing no 
harm to patients, supplemental oxygen therapy is still being used. Unfortunately, this may be due 
to the lack of information on the long-term morbidity and mortality of oxygen use. At this time 
there is not enough evidence to determine the long-term effects of supplemental oxygen use in 
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uncomplicated AMIs. Further large random control studies that are focused on the long-term 
effects of supplemental oxygen are needed before any guidelines should be implemented to 
regulate the use of oxygen in normoxic AMI patients. 
 18 
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Table I: Quality Assessment of Reviewed Articles 
Study Design 
Downgrade Criteria Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision Publication bias 
Rawles and 




Not Serious Not Serious Not Serious Unlikely N/A Low 




Not Serious Not Serious Not Serious Unlikely N/A Moderate 




Table II – Details of patients with define myocardial infarction. Rawles and Kenmure 10  
 
 Air Group (95% CI) Oxygen Group (95% CI) P Value 
No of patients 77 80 NS 
No of men 61 63 NS 
Mean age (years) 56.4 (54.8 – 58) 55.1 (53.3 - 56.9) NS 
Mean serum AST level (IU/mL) 80.7 (67.5 – 93.9) 99.9 (85.7 - 114.1) <0.05 
Mean heart rate/min 72.7 (68.9 – 76.5) 77.0 (73.6 - 80.4) NS 
Atrial ectopic beats 35 34 NS 
Sinus tachycardia 11 23 <0.05 





Table III – Baseline Characteristics of Patients With Confirmed STEMI. Stub et al 12  
Characteristics Oxygen (n=218) Room Air (n=223) 
Age, mean (SD), years 63 (11.9) 62.6 (13.0) 
Male, n (%) 174 (79.8) 174 (78.0) 
Body mass index, median (IQR), kg/m2* 27.4 (25.1–31.1) 27.7 (24.7–30.8) 
Past history and risk factors, n (%)  
       Diabetes mellitus 37 (17.0) 41 (18.4) 
       Hypertension 130 (59.6) 123 (55.2) 
       Dyslipidemia 121 (55.5) 118 (52.9) 
       Current or ex-smoker†  141 (65.3) 165 (74.3) 
       Peripheral vascular disease 4 (1.8) 11 (4.9) 
       Stroke 11 (5.0) 15 (6.7) 
       Ischemic heart disease 38 (17.4) 40 (17.9) 
                 Previous PCI 24 (11.0) 26 (11.7) 
                 Previous CABG 4 (1.8) 3 (1.3) 
                 Medication only 8 (3.7) 12 (5.4) 
       Creatinine >120 μmol/L 17 (7.8) 19 (8.5) 
Status on arrival of paramedics  
       Heart rate, median (IQR), bpm 74.0 (61.0-84.0) 72.0 (60.0–80.3) 
       Systolic blood pressure, median (IQR), mmHg 130.0 (105.0–150.0) 130.0 (110.0–150.0) 
       Oxygen saturation, median (IQR), % 98.0 (97.0–99.0) 98.0 (97.0–99.0) 
       Pain score, median (IQR) 7.0 (5.0–9.0) 7.0 (5.0–8.0) 
CABG indicates coronary artery bypass grafting; IQR, interquartile range; PCI, percutaneous coronary intervention; and STEMI, ST-
segment-elevation myocardial infarction. 
*Available in 280 of 441 patients 
† P for difference <0.05. 
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Table IV – Measures of infarct Size in Patients With Confirmed STEMI 
End Point Oxygen (n=218) Room Air (n=223) 





    Sample size, n 200 205   
    Median peak (IQR), μg/L 65.7 (30.1–145.1) 62.1 (19.2–144.0)   
    Geometric mean peak (95% CI), μg/L 57.4 (48.0–68.6) 48.0 (39.6–58.1) 1.20 (0.92–1.55) 0.18 
    Median AUC72  (95% CI), μg/L 2336.4 (965.6-5043.1) 1995.5 (765.7–4426.0)   
    Geometric mean AUC72 (95% CI), μg/L 2000.4 (1692.8–2363.9) 1647.9 (1380.1–1967) 1.21 (0.95–1.55) 0.12 
Creatine Kinase, U/L 
    Sample size, n 217 222   
    Median peak  (IQR), U/L 2073 (1065–3753) 1727 (737–3598)   
    Geometric mean peak (95% CI), μg/L 1948 (1721–2205) 1543 (1341–1776) 1.26 (1.05–1.52) 0.01 
    Median AUC72 (95% CI), μg/L 64,620 (35,751–107,066) 51,757 (29,141–106,029)   
    Geometric mean AUC72 (95% CI), μg/L 60,395 (54,185–67,316) 50,726 (44,861–57,358) 1.19 (1.01–1.40) 0.04 
Infarct size on CMR* 
    Sample size, n 61 66   
    Median (IQR), g 20.3 (9.6–29.6) 13.1 (5.2–23.6)  0.04 
    Geometric mean peak (95% CI), g 14.6 (11.3–18.8) 10.2 (7.7–13.4) 1.43 (0.99–2.07) 0.06 
    Median (IQR) proportion of LB mass, % 12.6 (6.7–19.2) 9.0 (4.1–16.3)  0.08 
     Geometric mean (95% CI) proportion of LB     
    mass, g 
10.0 (9.1–12.5) 7.3 (5.7–9.3) 1.38 (0.99–1.92) 0.06 
     ECG ST-segment resolution >70%, measured 1 d     
     after hospital admission, n (%) 
132 (62.0) 149 (69.6)  0.10 
AUC indicates area under the curve; CI, confidence interval; CMR, cardiac magnetic resonance imaging; IQR, interquartile range; LV, left 
ventricular; and STEMI, ST-segment-elevation myocardial infarction. 
*CMR conducted six-month follow-up in 139 of 441 patients 
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Figure I – Patient selection and randomization flowchart. STEMI indicates ST-segment-elevation myocardial infarction 
 
